Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gamma-glutamyltransferase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Gamma-glutamyltransferase. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-003597-17 Sponsor Protocol Number: FAR-NP-2014-01 Start Date*: 2014-11-17
    Sponsor Name:Josep Llop Talaveron
    Full Title: Pilot, randomized, double-blind clinical trial to determine the phytosterolaemia in hospitalized patients treated with total parenteral nutrition and gamma-glutamyltransferase alteration
    Medical condition: Adult hospitalized patients with parenteral nutrition and liver disfunction
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004871 10008641 Cholestatic liver disease LLT
    17.0 10022117 - Injury, poisoning and procedural complications 10074151 Parenteral nutrition associated liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000048-24 Sponsor Protocol Number: COMB-BO8 Start Date*: 2018-12-28
    Sponsor Name:Sahlgrenska University Hospital/VGR
    Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL ON THE EFFICACY OF VARENICLINE AND BUPROPION, IN COMBINATION AND ALONE, FOR THE TREATMENT OF ALCOHOL USE DISORDER
    Medical condition: Alcohol Use Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004465-41 Sponsor Protocol Number: P04612 Start Date*: 2006-01-27
    Sponsor Name:SCHERING-PLOUGH
    Full Title: A multi-center, open-label trial evaluating the Efficacy, Safety and the Impact on Quality of Life of Infliximab Therapy in patients with moderate to severe psoriasis not responding and/or intolera...
    Medical condition: Moderate to severe psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002456-90 Sponsor Protocol Number: 14060802 Start Date*: 2015-02-13
    Sponsor Name:Stockholm Centre for Dependency Disorders, Department of Clinical Neuroscience, Karolinska Institutet
    Full Title: Integrated Exposure-Based Therapy for Co-occurring Posttraumatic Stress Disorder and Alcohol Dependence: Effects of the FAAH inhibitor PF-04457845 on Extinction. A Randomized Controlled Trial.
    Medical condition: Current Posttraumatic Stress Disorder (PTSD) and Current Alcohol Dependence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003343-11 Sponsor Protocol Number: GLP1ALCOHOL Start Date*: 2017-04-12
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence?
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10001125 Addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007170-30 Sponsor Protocol Number: TUD-Psslan-031 Start Date*: 2008-06-03
    Sponsor Name:Technical University of Dresden, faculty of medicine
    Full Title: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and f...
    Medical condition: Psoriasis vulgaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000829-55 Sponsor Protocol Number: PSILO4ALCO Start Date*: 2020-12-16
    Sponsor Name:Psychiatric Centre Copenhagen
    Full Title: Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.
    Medical condition: Alcohol Use Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    21.1 10037175 - Psychiatric disorders 10001590 Alcohol addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001431-56 Sponsor Protocol Number: NUT-2/PBC Start Date*: 2022-03-07
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patien...
    Medical condition: primary biliary cholangitis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) FI (Prematurely Ended) BE (Completed) FR (Completed) NO (Prematurely Ended) NL (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000085-39 Sponsor Protocol Number: P04271 Start Date*: 2005-09-08
    Sponsor Name:Schering-Plough Research Institute
    Full Title: An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis
    Medical condition: Moderate to severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) PT (Completed) DE (Completed) GB (Completed) SE (Completed) ES (Completed) GR (Completed) AT (Completed) FI (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005367-28 Sponsor Protocol Number: P04563 Start Date*: 2006-09-18
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Long-Term Efficacy and Safety Study of Infliximab in the Treatment of Moderate to Severe Plaque-type Psoriasis
    Medical condition: Moderate to severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000535-26 Sponsor Protocol Number: P05133 Start Date*: 2007-06-04
    Sponsor Name:SCHERING-PLOUGH
    Full Title: SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO)
    Medical condition: Patients with moderate to severe psoriasi.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011041-12 Sponsor Protocol Number: ET-A-018-09 Start Date*: 2009-07-23
    Sponsor Name:Pharma Mar S.A.
    Full Title: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.
    Medical condition: Pretreated Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001371-37 Sponsor Protocol Number: GDM-TREAT Start Date*: 2012-07-10
    Sponsor Name:Dr. med. Tina Vilsbøll
    Full Title: The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus
    Medical condition: Gestational diabetes mellitus Non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10018210 Gestational diabetes mellitus LLT
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-005006-62 Sponsor Protocol Number: ASZ-001 Start Date*: 2019-12-10
    Sponsor Name:Albert Schweitzer hospital
    Full Title: Pharmacokinetics of Paracetamol before and after Roux-en-Y gastric bypass
    Medical condition: Roux-en-Y gastric bypass
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10033762 Paracetamol LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003419-68 Sponsor Protocol Number: HepBTer Start Date*: 2020-12-18
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients
    Medical condition: Chronic hepatitis B infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10052552 Hepatitis B virus LLT
    20.1 10021881 - Infections and infestations 10047450 Viral hepatitis B LLT
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    20.0 10021881 - Infections and infestations 10019737 Hepatitis B carrier LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002189-12 Sponsor Protocol Number: P04422 Start Date*: 2005-12-07
    Sponsor Name:Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.
    Full Title: A randomized, multicenter, international, open-label study of infliximab plus methotrexate versus methotrexate (MTX) alone for the treatment of MTX naïve subjects with Active Psoriatic Arthritis Ra...
    Medical condition: Pacienti s aktívnou psoriatickou artiritídou.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10037161 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) SI (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-000982-51 Sponsor Protocol Number: P05336 Start Date*: 2009-07-01
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
    Medical condition: Moderate-to-severe active axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058338 Spondylarthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed) DE (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004287-30 Sponsor Protocol Number: LAL-CL06 Start Date*: 2014-06-19
    Sponsor Name:Alexion Pharmaceuticals inc
    Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency (LALD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10024579 Lysosomal storage disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000454-12 Sponsor Protocol Number: P05315 Start Date*: 2009-03-03
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.
    Medical condition: Moderate to severe plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    11.0 10037153 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Prematurely Ended) DK (Completed) HU (Prematurely Ended) FR (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002670-22 Sponsor Protocol Number: P04807 Start Date*: 2007-10-31
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1). C...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) BE (Completed) HU (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA